imvax_inc Profile Banner
Imvax, Inc. Profile
Imvax, Inc.

@imvax_inc

Followers
112
Following
10
Statuses
204

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.

Philadelphia, Pennsylvania
Joined November 2021
Don't wanna be here? Send us removal request.
@imvax_inc
Imvax, Inc.
2 days
IGV-001 is a personalized therapy that aims to induce antitumor immunity in newly diagnosed patients with #GBM. It includes the patient’s own tumor cells plus a molecule called IMV-001 placed into biodiffusion chambers that are implanted in the patient.
Tweet media one
Tweet media two
0
0
0
@imvax_inc
Imvax, Inc.
4 days
Today on #WorldCancerDay we’re emphasizing the importance of people-centered care. Visit Imvax partner @HeadfortheCure to read about some inspiring journeys of resilience and hope from brain cancer patients: #UnitedByUnique
Tweet media one
0
0
1
@imvax_inc
Imvax, Inc.
11 days
Today we announced the completion of a $29 million financing round. We are also on track to report topline results from our Phase 2b trial of #IGV001 in patients with newly diagnosed #glioblastoma in mid-2025. More:
Tweet media one
0
0
1
@imvax_inc
Imvax, Inc.
15 days
#Glioblastoma is a complex and deadly brain cancer that affects over 14,000 people in the U.S. each year. Learn more about this devastating #braincancer and the need for innovative treatments like IGV-001 here: #IGV001 #GBM #cancerresearch
0
0
1
@imvax_inc
Imvax, Inc.
26 days
Members of the Imvax leadership team have touched down in San Francisco for #JPM25. We look forward to engaging in discussions with investors and key industry players around what’s in store for #biotech and Imvax in 2025.
Tweet media one
0
1
4
@imvax_inc
Imvax, Inc.
29 days
2024 was filled with special moments, from IGV-001 receiving Fast Track designation by the #FDA to presenting on the development of #IGV001 at #ESMO24, #SITC24 & #SNO24. We look forward to an exciting 2025 as we plan to announce results from our Ph. 2b trial of IGV-001 in #GBM.
0
0
1
@imvax_inc
Imvax, Inc.
2 months
Happy Holidays from Team Imvax! Wishing everyone a restful and joyous holiday season. We look forward to continuing our work for #glioblastoma patients in the new year!
Tweet media one
0
0
1
@imvax_inc
Imvax, Inc.
2 months
We’re committed to developing a new approach to treating #glioblastoma. Learn more about our lead product candidate, #IGV001, for patients with newly diagnosed #GBM, now in a Phase 2b trial:
@imvax_inc
Imvax, Inc.
1 year
Glioblastoma is a difficult to treat #braincancer that is nearly always fatal. At Imvax, we’re leveraging our unique immunotherapy platform to develop a pipeline of personalized, whole tumor-derived treatments, including #IGV001 for #glioblastoma. #Goldspire #cancerresearch
0
0
1
@imvax_inc
Imvax, Inc.
2 months
This week in Boston, Imvax CMO David Andrews, M.D. and COO Sean Hemingway will present on the development and manufacturing of IGV-001 at the Personalized Cancer Vaccine Summit. For more about the event: #IGV001 #Goldspire #immunooncology #cancerresearch
0
0
1
@imvax_inc
Imvax, Inc.
2 months
Happy Thanksgiving to our incredible team and partners!
Tweet media one
0
0
0
@imvax_inc
Imvax, Inc.
3 months
We’re on the ground at #SNO2024! Stop by our booth at the George R. Brown Convention Center in Houston to connect with our team. #cancerresearch #braincancer #neurooncology #glioblastoma #IGV001 #Goldspire
Tweet media one
0
0
2
@imvax_inc
Imvax, Inc.
3 months
If you are at #SNO2024 this week, we invite you to stop by our symposium today at 12:45 pm CST. We have a great agenda planned, featuring an overview of #Goldspire & the latest developments around our lead candidate #IGV001 for #GBM. Reach out to us for more details.
Tweet media one
Tweet media two
0
0
2
@imvax_inc
Imvax, Inc.
3 months
#Goldspire fits within the SOC for patients with resectable solid tumors. After the biodiffusion chamber implant/removal process, the patient’s immune system training begins & they can continue with the SOC. Learn more:
Tweet media one
0
0
1
@imvax_inc
Imvax, Inc.
3 months
We will present oral and poster presentations on the development of our lead candidate #IGV001 at the 2024 SNO Annual Meeting next week. Details: @NeuroOnc #SNO2024 #braincancer #cancerresearch
Tweet media one
0
0
2
@imvax_inc
Imvax, Inc.
3 months
We are proud to be a part of the #STEM community, which makes up approximately 25% of the U.S. workforce. This #NationalSTEMDay, hear from some of our team on why they decided to pursue a career in STEM and the value of STEM education:
0
0
1
@imvax_inc
Imvax, Inc.
3 months
This weekend at #SITC2024, Imvax CSO Mark A. Exley, Ph.D. will present data on the use of our Goldspire® platform to enable durable and system immunity in multiple solid cancer types. Stop by his poster on Saturday, Nov 9th! #Goldspire #cancerresearch
Tweet media one
0
0
2
@imvax_inc
Imvax, Inc.
3 months
Our #Goldspire platform enables complete patient tumor tissue processing and product preparation in less than 24 hours, allowing for implantation into the patient the next day. Learn more about the advantages of Goldspire®:
Tweet media one
0
0
1
@imvax_inc
Imvax, Inc.
4 months
This month at #EANO2024, we presented blinded safety data from our ongoing Phase 2b study of #IGV001 in patients with #glioblastoma. IGV-001 is the first product candidate developed with our Goldspire® platform. #CancerResearch
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
1
2
@imvax_inc
Imvax, Inc.
4 months
#ICYMI: We recently published preclinical research to further expand our findings on the use of IGV-001 in #GBM & support the use of #Goldspire to generate anti-tumor immunity in multiple solid tumors. Read the full paper here: #cancerresearch @AACR
Tweet media one
0
0
2
@imvax_inc
Imvax, Inc.
4 months
The #braintumor community of Greater Philly came together on Oct 13  at the Race for Hope to raise awareness to support the needs of patients and their families. We were honored to sponsor & join in the race. Thank you to our partner, @NBTStweets, for hosting this great event.
Tweet media one
0
1
5